[Current Data from the National Registry for Prostate Cancer (ProNAT) by d-uo].

INTRODUCTION

The National Prostate Cancer Registry (ProNAT) of the German Uro-Oncologists (d-uo) was launched in 2022 to provide a real-world, cross-sector overview of prostate cancer management in Germany. Building on the VERSUS study, ProNAT collects detailed longitudinal data on quality of care, guideline adherence, and therapeutic strategies.

MATERIAL AND

METHODS

ProNAT is a non-interventional, prospective, multicenter registry (DRKS00030737, ethics approval Berlin 2018). Patients with histologically confirmed prostate cancer from 55 urology centers are included. Collected data comprise demographics, clinical parameters, tumor stage, treatment modality, comorbidities, and psycho-oncological support.

RESULTS

As of August 2025, 3,417 patients were enrolled (analyzable n = 3,052; median age 69 years). Most patients (91.1%) had ECOG 0-1. Common comorbidities included arterial hypertension (30.6%), diabetes mellitus (8.2%), and cardiovascular disease (9.1%). Metastatic disease at diagnosis was present in 6.7%, while 77.6% had T1-T2 tumors. Multiparametric MRI prior to biopsy was performed in 36.6%. Curative surgery was robot-assisted in 87.7 of cases. Among Gleason 3 + 3 cases, 35.1% underwent active surveillance and 37.8% underwent surgery. Psycho-oncological support was documented in only 18.2%.

CONCLUSION

ProNAT provides the first comprehensive real-world dataset on outpatient prostate cancer care in Germany. Findings demonstrate progress in diagnostic guideline adherence but highlight under-utilization of psycho-oncological services and multidisciplinary planning. With continued patient enrollment, ProNAT will enable more detailed analyses of treatment sequences and care quality.